Integration of PARP-inhibitors in ovarian cancer therapy

Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. The availability of this new class of drugs has changed the clinical management of OC ensuring an unprecedented advance in such an aggressive cancer. Three oral PARP-I are currently available: olaparib, niraparib and rucaparib. Another two are in active clinical exploration: veliparib and talazoparib. Here the authors report clinical data with PARP-I with a particular emphasis on the phase II and III trials that support PARP-I approval by regulatory agencies in OC patients.

Download Full-text

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2020.102040 ◽

2020 ◽

Vol 87 ◽

pp. 102040 ◽

Cited By ~ 1

Author(s):

Ilary Ruscito ◽

Filippo Bellati ◽

Isabelle Ray-Coquard ◽

Mansoor Raza Mirza ◽

Andreas du Bois ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Controlled Trials ◽

Phase Ii ◽

Meta Analysis ◽

Recurrent Ovarian Cancer ◽

Parp Inhibitors ◽

Controlled Trials ◽

Randomized Controlled

Download Full-text

PARP inhibitors in the ovarian cancer therapy

Ginekologia Polska ◽

10.17772/gp/59268 ◽

2016 ◽

Vol 87 (02) ◽

pp. 131-134 ◽

Cited By ~ 1

Author(s):

Maksymilian Kruczała ◽

Aleksandra Grela-Wojewoda ◽

Ida Cedrych

Keyword(s):

Ovarian Cancer ◽

Cancer Therapy ◽

Parp Inhibitors

Download Full-text

The forefront of ovarian cancer therapy: update on PARP inhibitors

Annals of Oncology ◽

10.1016/j.annonc.2020.06.004 ◽

2020 ◽

Vol 31 (9) ◽

pp. 1148-1159 ◽

Cited By ~ 10

Author(s):

M.R. Mirza ◽

R.L. Coleman ◽

A. González-Martín ◽

K.N. Moore ◽

N. Colombo ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Therapy ◽

Parp Inhibitors

Download Full-text

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer

Journal of Oncology ◽

10.1155/2010/151750 ◽

2010 ◽

Vol 2010 ◽

pp. 1-6 ◽

Cited By ~ 9

Author(s):

Lilian T. Gien ◽

Helen J. Mackay

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Anticancer Agents ◽

Excision Repair ◽

Parp Inhibitors ◽

Parp Inhibition ◽

Brca1 And Brca2 ◽

New Class ◽

Base Excision ◽

Novel Target

Poly(ADP-ribose) polymerase-1 (PARP-1) is an important novel target in cancer therapy. This enzyme is essential in the repair of single-stranded breaks in DNA via the base excision repair pathway. Drugs which inhibit PARP are emerging as a promising new class of anticancer agents particularly effective against tumors which have lost homologous recombination (HR) through loss of functional BRCA1 and BRCA2. PARP inhibitors potentially represent a major breakthrough for patients with hereditary BRCA-associated cancers. Furthermore their role in sporadic epithelial ovarian cancer is emerging with identification of additional subpopulations of women who may benefit a priority. This paper will summarize the mechanism of action of PARP inhibition and its role in the treatment of BRCA1- and 2-associated cancers. We will then expand on the broader relevance and future directions for PARP inhibition in the clinical setting.

Download Full-text